Study S001847

Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT03136484
Acronym: SUSTAIN 8
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 788
Start: 2017-03-15
Primary completion: 2018-10-16
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: DRUG:Semaglutide; DRUG:Canagliflozin; DRUG:Placebo (canagliflozin); DRUG:Placebo (semaglutide)
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: EUDRACT_NUMBER:2016-000989-35; OTHER:U1111-1180-3651; NIH:2016

Registered primary outcomes

Change in HbA1c [Week 0, week 52]

Linked records (6)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0010237	Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes. Natale P, The Cochrane database of systematic reviews	2025	Systematic review	PMID 39963952 DOI	cites ClinicalTrials.gov:NCT03136484; registry reference DERIVED:39963952
R0020952	Cost-Effectiveness of Semaglutide vs. Empagliflozin, Canagliflozin, and Sitagliptin for Treatment of Patients with Type 2 Diabetes in Denmark: A Decision-Analytic Modelling Study. Pulleyblank R, PharmacoEconomics - open	2023	Nonrandomized study	PMID 37178435 DOI	cites ClinicalTrials.gov:NCT03136484; registry reference DERIVED:37178435
R0023212	Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting. Stafford S, Applied health economics and health policy	2022	Randomized trial	PMID 35344191 DOI	cites ClinicalTrials.gov:NCT03136484
R0018492	Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis. Lingvay I, The Journal of clinical endocrinology and metabolism	2020	Systematic review	PMID 32827435 DOI	cites ClinicalTrials.gov:NCT03136484; registry reference DERIVED:32827435
R0024549	Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. McCrimmon RJ, Diabetologia	2020	Randomized trial	PMID 31897524 DOI	cites ClinicalTrials.gov:NCT03136484; registry reference RESULT:31897524
R0019398	Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lingvay I, The lancet. Diabetes & endocrinology	2019	Randomized trial	PMID 31540867 DOI	cites ClinicalTrials.gov:NCT03136484; registry reference RESULT:31540867